Pre-operative plasma levels of fibrinogen, plasma prothrombin time, activated partial thromboplastin time and thrombin time (TT) were retrospectively examined in 105 patients with ovarian carcinoma and 21 control patients with benign ovarian tumour. Plasma cancer antigen 125 (CA-125) levels, pathological type, age, body mass index and blood group were evaluated. The TTs of patients with stage III and stage IV ovarian carcinoma were significantly shorter than in controls. Levels of plasma fibrinogen in patients with stage III and IV ovarian carcinoma were higher than those in patients with stage I and II ovarian carcinoma and the controls. There was a positive relationship between levels of plasma CA-125 and plasma fibrinogen in patients with stage II malignancy. There were no significant differences between plasma fibrinogen levels in patients of different age, BMI, blood group and pathological type. Shorter TT was an indication of advanced stage ovarian carcinoma, and fibrinogen was associated with the peritoneal carcinomatosis of ovarian carcinoma.
RicklesFRLevineMEdwardsRL: Hemostatic alterations in cancer patients. Cancer Metastasis Rev1992; 11: 237–248 (DOI: 10.1007/BF01307180).
2.
ZacharskiLRMemoliVAOrnsteinDL: Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst1993; 85: 1225–1230.
3.
NaschitzJEYeshurunDLevLM: Thromboembolism in cancer. Changing trends. Cancer1993; 71: 1384–1390.
4.
BorgonoCADiamandisEP: The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer2004; 4: 876–890 (DOI: 10.1038/nrc1474).
5.
WinterPC: The pathogenesis of venous thromboembolism in cancer: Emerging links with tumour biology. Hematol Oncol2006; 24: 126–133.
6.
LeeJHRyuKWKimS: Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor. Hepatogastroenterology2004; 51: 1860–1863.
7.
YamashitaHKitayamaJNagawaH: Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn J Clin Oncol2005; 35: 595–600.
8.
JonesJMMcGonigleNCMcAnespieM: Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer2006; 53: 97–101.
9.
PalumboJSKombrinckKWDrewAF: Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood2000; 96: 3302–3309.
10.
HernandezEDonohueKAAndersonLL: The significance of thrombocytosis in patients with locally advanced cervical carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol2000; 78: 137–142.
11.
SymbasNPTownsendMFEl-GalleyR: Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int2000; 86: 203–207.
12.
ShimadaHOohiraGOkazumiS: Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg2004; 198: 737–741.
13.
IkedaMFurukawaHImamuraH: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol2002; 9: 287–291.
14.
KohSCKhalilRLimFK: The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost2006; 12: 3–8.
15.
SampsonMTKakkarAK: Coagulation proteases and human cancer. Biochem Soc Trans2002; 30: 201–207 (DOI: 10.1042/BST0300201).
16.
TopalakOSaygiliUSoyturkM: Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: A comparative study. Gynecol Oncol2002; 85: 108–113.
17.
SaygiliUGucluSUsluT: The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. Int J Gynecol Cancer2002; 12: 438–442.
18.
NagyJAMeyersMSMasseEM: Pathogenesis of ascites tumor growth: Fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res1995; 55: 369–375.
19.
PalumboJSPotterJMKaplanLS: Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res2002; 62: 6966–6972.
20.
TsaiAWCushmanMRosamondWD: Coagulation factors, inflammation markers, and venous thromboembolism: The longitudinal investigation of thromboembolism etiology (LITE). Am J Med2002; 113: 689–690.
21.
MarchiRRamirezY LópezNagaswamiC: Haemostatic changes related to fibrin formation and fibrinolysis during the first trimester in normal pregnancy and in recurrent miscarriage. Thromb Haemost2007; 97: 552–557.
22.
CushmanMTsaiAWWhiteRH: Deep vein thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology. Am J Med2004; 117: 19–25.
23.
HirohashiTYoshinagaKSakuraiT: Study of the echocardiographic diagnosis of acute pulmonary thromboembolism and risk factors for venous thromboembolism. J Cardiol2006; 47: 63–71.
24.
TateoSMereuLSalamanoS: Ovarian cancer and venous thromboembolic risk. Gynecol Oncol2005; 99: 119–125.
25.
StreiffMBSegalJGrossmanSA: ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer2004; 100: 1717–1723.
26.
TiradoIMateoJSoriaJM: The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost2005; 93: 468–474.
27.
MatsuuraYRobertsonGMarsdenDE: Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol2007; 104: 406–410 (Epub 2 October 2006).
